Clinical Trials

Phase NA Not yet recruiting

120 enrolled

Myasthenia Gravis

NCT07499323 2026-04-08

Talquetamab in Patients With Refractory Generalized Myasthenia Gravis

2 enrolled

Myasthenia Gravis

NCT06680037 2026-04-07

A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders

Phase 1 Recruiting

32 enrolled

Multiple Sclerosis, Myasthenia Gravis, Neuromyelitis Optica, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT06987539 2026-04-07

THYME

Phase 2 Recruiting

Myasthenia Gravis

NCT06193889 2026-04-06

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

Phase 2/3 Recruiting

66 enrolled

Autoimmune Diseases, Myasthenia Gravis

NCT06704269 2026-04-06

Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis

Phase 1/2 Recruiting

Myasthenia Gravis

NCT06744920 2026-04-06

RELIEVE

180 enrolled

Myasthenia Gravis

NCT06607627 2026-04-01

PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis

Myasthenia Gravis

NCT06517758 2026-03-30

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

Phase 2 Not yet recruiting

146 enrolled

Myasthenia Gravis

NCT07501702 2026-03-30

ETNA

30 enrolled

Myasthenia Gravis

NCT06471361 2026-03-27

A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis

Phase 3 Completed

31 enrolled 11 charts

Myasthenia Gravis

NCT07246564 2026-03-27

Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis

Phase 4 Recruiting

40 enrolled

Myasthenia Gravis

NCT05403541 2026-03-25

Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis

240 enrolled

Myasthenia Gravis

NCT06799247 2026-03-24

Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis

100 enrolled

Myasthenia Gravis

NCT06491238 2026-03-23

MG-Ex

20 enrolled

Myasthenia Gravis

NCT06463587 2026-03-19

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

264 enrolled

Myasthenia Gravis

NCT07413835 2026-03-18

Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)

Phase 3 Not yet recruiting

6 enrolled

Myasthenia Gravis

NCT07463521 2026-03-17

MyVision

120 enrolled

Myasthenia Gravis

NCT07478172 2026-03-17

Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease

50 enrolled

Amyotrophic Lateral Sclerosis, Charcot-Marie-Tooth Disease, Glycogen Storage Disease Type II, Muscular Atrophy, Spinal, Myasthenia Gravis, Neuromuscular Diseases, Spastic Paraplegia, Hereditary, Lambert-Eaton Myasthenic Syndrome, Postpoliomyelitis Syndrome, Motor Neuron Disease, Mitochondrial Myopathies, Myopathies, Nemaline, Myositis, Inclusion Body, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Muscular Dystrophy, Facioscapulohumeral, Myopathies, Structural, Congenital, Postural Orthostatic Tachycardia Syndrome

NCT05265273 2026-03-13

A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

Phase 2/3 Recruiting

Myasthenia Gravis

NCT07470151 2026-03-13

Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases

Phase 3 Not yet recruiting

Autoimmune Diseases, Lupus Erythematosus, Systemic, Myasthenia Gravis, Scleroderma, Diffuse

NCT07465289 2026-03-11

A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

100 enrolled

Myasthenia Gravis

NCT04524273 2026-03-10

MINT

238 enrolled 36 charts

Myasthenia Gravis

NCT06456580 2026-03-10

A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

Phase 1 Not yet recruiting

180 enrolled

Myasthenia Gravis

NCT07304154 2026-03-10

A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases

52 enrolled

Multiple Sclerosis, Myasthenia Gravis, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT07039916 2026-03-06

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

Phase NA Not yet recruiting

231 enrolled

Autoimmune Diseases, Myasthenia Gravis

NCT07298928 2026-03-06

A Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia Gravis

30 enrolled

Myasthenia Gravis

NCT04951622 2026-03-03

A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

Phase 2 Active not recruiting

199 enrolled 11 charts

Myasthenia Gravis

NCT00716066 2026-02-27

Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases

53 enrolled

CNS

Rasmussen subacute encephalitis, Autoimmune Diseases, Myasthenia Gravis, Neuromyelitis Optica, Lambert-Eaton Myasthenic Syndrome, Stiff-Person Syndrome, Autoimmune Diseases of the Nervous System, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Vasculitis, Central Nervous System, Opsoclonus-Myoclonus Syndrome

NCT04225871 2026-02-27

RAISE-XT

200 enrolled

Myasthenia Gravis

NCT06626919 2026-02-25

A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

Phase 1 Recruiting

30 enrolled

Autoimmune Diseases, Muscular Diseases, Myasthenia Gravis, Muscle Weakness, Autoimmune Diseases of the Nervous System, Neuromuscular Manifestations

NCT07215949 2026-02-23

Zilucoplan for Severe gMG Exacerbations

Phase 1/2 Active not recruiting

Myasthenia Gravis

NCT06359041 2026-02-20

RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

Autoimmune Diseases, Myasthenia Gravis

NCT05644561 2026-02-19

Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)

Myasthenia Gravis

NCT04833894 2026-02-18

ADAPT Jr

Phase 2/3 Recruiting

Myasthenia Gravis

NCT05070858 2026-02-12

NIMBLE

Phase EARLY_PHASE1 Not yet recruiting

288 enrolled

Myasthenia Gravis

NCT06965309 2026-02-12

Efficacy and Safety of HN2301 in Refractory Myasthenia Gravis(MG)

Phase NA Terminated

9 enrolled

Myasthenia Gravis

NCT07250750 2026-02-11

Synergy-MG

Phase 1/2 Recruiting

96 enrolled

Myasthenia Gravis

NCT07392528 2026-02-11

Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases